A Comparative Clinical Study To Evaluate The Efficacy Of Lipistab Tablet (Kalpit Yog) With Or Without Lekhniya Basti In The Management Of Medovaha Sroto Dushti W.S.R To Hyperlipidemia.
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- It will lower the values of the lipid profile, including serum total cholesterol, triglycerides, low-density lipoproteins (LDL), high-density lipoproteins (HDL), very low-density lipoproteins (VLDL), and the ratio of HDL to total cholesterol.
研究概览
简要总结
The total of 60 patients will be selected who are between age group of 20 to 60 years of either sex who are diagnosed with Medovaha Sroto Dushti on the basis of sign/symptoms and Lab examination. Patients will be divided into two groups (Trial Group A and Trial Group B).
Group A will be given oral administration of Lipistab Tablet and Lekhniya Basti and Group B will be given oral administration of Lipistab Tabletand conduct a clinical study
to evaluate the effect of oral administration of Lipistab Tabletin the management of Medovaha Sroto Dushti w.s.r. Hyperlipidemia;
to evaluate the effect of oral administration Lipistab Tablet with Lekhniya Basti in the management of Medovaha Sroto Dushti w.s.r. Hyperlipidemia and
to compare the effect of oral administration of Lipistab Tablet with and without Lekhniya Basti in the management of Medovaha Sroto Dushti w.s.r. Hyperlipidemia.
The total duration of study will be 18 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 20.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients willing for study.
- •Patients between the age of 20 and 60 years.
- •If the values of Lipid Profile exceed than normal values.
排除标准
- •1.Patients not willing for study.
- •2.Patients having serious cardiac problems as- Myocardial Infarction, malignant hypertension, cardiac failure.
- •3.Patients having major illness like- IDDM and chronic uncontrolled DM II.
- •4.Patients having any serious renal disorder, untreated Thyroid Disorder.
- •5.Drug induced Hyperlipidemia e.g. -Glucocorticoid induced.
结局指标
主要结局
It will lower the values of the lipid profile, including serum total cholesterol, triglycerides, low-density lipoproteins (LDL), high-density lipoproteins (HDL), very low-density lipoproteins (VLDL), and the ratio of HDL to total cholesterol.
时间窗: Assessment will be done in both the groups: | 1.Day 20:At the end of the Basti. (for Group A) | 2.Day 40:At the end of treatment. (For the Group B) | 3.Day 60:At the time of follow up (For both the Groups A and B).
次要结局
- Measurable improvement in the following subjective sign & symptoms:
研究者
Dr Paramvir Singh
Dayanand Ayurvedic College